Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of May 2022, specifically dated May 12, 2022. The document serves as a report of a foreign private issuer regarding a corporate governance event rather than a financial performance report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document contains no financial statements or operational metrics.
Material Changes
There are no material financial changes reported. The only material event disclosed is the adjournment of the Annual General Meeting of Shareholders originally scheduled for May 12, 2022, due to a lack of the required legal quorum.
Outlook and Management Commentary
Management has announced that the Annual General Meeting will reconvene on May 13, 2022, at 3:00 p.m. Israel time at the Company's office. No guidance, risk factors, or unusual items were disclosed in this specific filing.
Key Facts for Investors to Verify
- The Annual General Meeting was adjourned on May 12, 2022, due to insufficient shareholder attendance (lack of quorum).
- The meeting is rescheduled for May 13, 2022, at 3:00 p.m. Israel time.
- This filing does not contain financial results; investors should refer to Form 20-F or other periodic reports for financial data.